BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medtronic, Inc. (MDT) to Seek Expanded CRT Indication on Biventricular Pacing Data


5/14/2013 9:07:11 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Medtronic says it plans use data from a study of biventricular pacing of the heart's 2 lower chambers to back an expaned indication for its cardiac rhythm therapy devices. Medtronic (NYSE:MDT) plans to use new study results to ask the FDA to expand the indication for its cardiac resynchronization therapy devices, to include patients with atrioventricular block and left ventricular systolic dysfunction. A recent study published in the New England Journal of Medicine showed that simultaneously pacing the lower chambers of the heart with a CRT device significantly improves heart failure symptoms and quality of life in some patients with heart disease. “Biventricular pacing was superior to conventional right ventricular pacing in patients with atrioventricular block and left ventricular systolic dysfunction with NYHA class I, II, or III heart failure,” the study’s authors conclude in the April 25 edition of NEJM.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES